Clinical Trials Arena May 17, 2024
Senator Sanders took another swipe at the US prices of Novo Nordisk’s blockbuster GLP-1 receptor agonist drugs Ozempic and Wegovy.
US Senator Bernie Sanders has ramped up the pressure on Novo Nordisk after launching an investigation into GLP-1 agonist prices last month, warning in a report that the blockbuster drugs could “bankrupt our entire healthcare system”.
Last month, Sanders, who chairs the Senate Health, Education, Labor, and Pensions (HELP) Committee, announced the launch of an investigation into the US prices of the drugs in a stark letter to Novo Nordisk CEO Lars Fruergaard Jørgensen.
The announcement has now been followed with a report that indicates that if half of US adults with obesity opt for Novo Nordisks’s Wegovy...
Today's Sponsors
Today's Sponsor